Latest Headlines

Latest Headlines

Valeant plots big DTC push for Xifaxan while rival Actavis drug waits on DEA

Last week, the FDA approved both Valeant's Xifaxan and Actavis' new Viberzi to treat IBS-D. And now, the market will get to watch what Bernstein analyst Ronny Gal deemed an "interesting test" of two company approaches as the pair competes for uptake.

GI dealmaking pays off for Valeant, Actavis with same-day FDA nods in IBS

When it comes to go-aheads in irritable bowel syndrome, the FDA was busy Wednesday, approving the indication for a pair of drugs. And now, it looks as if recent M&A moves to acquire those drugs are about to pay off for Valeant and Actavis.

Actavis and Valeant go head-to-head on IBS as FDA OKs 2 new drugs

A little more than a year after Forest Labs bought out Furiex and its experimental irritable bowel syndrome drug eluxadoline in a $1.5 billion deal, Brent Saunders and Forest-buyer Actavis have scored an FDA approval that should surprise no one. And the agency paired the approval with a green light for Valeant's Xifaxan (rifaximin) in IBS, another drug that's been changing hands lately in the frenzy of M&A deals that has been changing the face of the industry.

Valeant chief Pearson won't be scared off by M&A 'bubble'

Valeant CEO J. Michael Pearson is plenty familiar with the pharma M&A space; after all, he's made scores of deals since taking up the post in 2008. And the way he sees it, with pickups happening left and right in the sector, some of pharma's recent acquisitions "are not going to work."

Report: Valeant in talks to buy Egypt's Amoun for up to $800M

Valeant's next pickup could come from the Middle East, where it's reportedly in deal talks with one of Egypt's largest drugmakers, Amoun.

Heavyweight investors sock big bucks into Valeant while others sell down

Valeant's former deal partner Bill Ackman is pretty rosy on his outlook for the company, as he's shown with a large share-grab and comparison to Warren Buffett's Berkshire Hathaway. But he's not the only one.

Valeant chief Pearson the next Warren Buffett? Deal partner Ackman thinks so

Activist investor Bill Ackman thinks an early-stage Berkshire Hathaway is out there--and he thinks it's Valeant Pharmaceuticals.

Ex-Sanofi exec Whitaker lands at Valeant in EVP role

After departing from Sanofi last year for the CEO's chair at Synta Pharmaceuticals, Anne Whitaker is now moving on to Valeant, where she'll step into the role of EVP and group chairman.

After topping Q1 estimates, Valeant hikes guidance on Salix buy

Following the fold-in of its recent $11.1 billion pickup of Salix Pharmaceuticals, on Wednesday, Valeant raised both its profit and revenue forecasts for the year. But things are already looking good for the Canadian drugmaker, which topped analyst estimates in both categories for Q1.

Here's an M&A strategy: Buy products, hike prices, watch sales grow

As the M&A wave sweeps over pharma, companies are wheeling and dealing for a number of different reasons. Slim-down strategies, tax break potential, portfolio diversification and other usual suspects have all driven transactions as of late--but the promise of price hikes has, too.
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • next ›
  • last »